Stavudine, Didanosine, and Zalcitabine

After the development and commercialization of zidovudine (as Retrovir®, also known as 3′-azido-3′-deoxythymidine or AZT) as the first anti-HIV compound in 1987, researchers logically turned to other nucleoside analogs in an attempt to expand the armamentarium against the disease. The next three compounds in this class to become commercially available were didanosine (as Videx®, Bristol Myers Squibb) in 1991, zalcitabine (as Hivid®, F. Hoffmann-La Roche) in 1992, and stavudine (as Zerit®, Bristol-Myers Squibb) in 1994 ( Fig. 1 ). These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.